tldrdailynews.com logo

AbbVie's Schizophrenia Drug Fails Trials, Boosting Bristol Myers Stock

1 min read
Source: STAT
AbbVie's Schizophrenia Drug Fails Trials, Boosting Bristol Myers Stock
Photo: STAT
TL;DR

AbbVie's experimental schizophrenia drug, emraclidine, acquired through a $9 billion deal with Cerevel Therapeutics, failed to show significant patient improvement in Phase 2 trials. The drug did not outperform a placebo on the Positive and Negative Syndrome Scale (PANSS), leading AbbVie to reassess its next steps.

Topics:businesshealth#abbvie#cerevel-therapeutics#clinical-trials#emraclidine#health#schizophrenia
Share this article
  1. Schizophrenia drug AbbVie picked up in $9 billion acquisition fails in key trials  STAT
  2. AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.  Barron's
  3. Crown jewel from AbbVie's Cerevel buyout fails two Phase 2 schizophrenia tests, Bristol Myers' stock soars  Endpoints News
  4. Bristol Myers Rockets 12% On AbbVie's Schizophrenia Failure  Investor's Business Daily
  5. JPMorgan sees AbbVie off about 10%, Bristol up 10%-15% on emraclidine news  TipRanks

Want the full story? Read the original reporting

Read on STAT